Arcellx, Inc. Material Event - The Acquisition is Complete

Here is the latest news from Arcellx, explained simply so you can get straight to the point.

1. What happened?

Gilead Sciences has officially acquired Arcellx. As of April 28, 2026, Arcellx is no longer an independent, public company; it is now a wholly owned subsidiary of Gilead. If you owned shares, they were canceled and converted into a cash payment of $115.00 per share. You also received one "Contingent Value Right" (CVR) for every share you previously owned.

2. Why did it happen?

Gilead acquired Arcellx to gain full control of its "CAR-T" technology, specifically the lead drug candidate, "anito-cel." By bringing Arcellx under its umbrella, Gilead accelerates its cancer-fighting pipeline by bypassing years of internal research and development.

3. What does this mean for your investment?

• The Ticker is Gone: The Arcellx ticker (ACLX) has been delisted from the Nasdaq. You will no longer see price updates or be able to trade the stock.
• The Cash Payout: You should see the $115.00 cash payment per share reflected in your brokerage account. If you do not see this, contact your broker immediately.
• The CVR (The "Bonus" Potential): You now hold a CVR for every share you owned. This is a contractual right to a potential $5.00 per share payment.
  • The Catch: This payment is not guaranteed. It will only be paid out in 2030 if the anito-cel drug hits $6 billion in total sales by the end of 2029.
  • Liquidity: You cannot trade this CVR on the stock market. It is essentially a "wait and see" asset that will sit in your account until the 2030 deadline.

4. Who is affected?

• Investors: You no longer own equity in Arcellx. Your ownership has been converted into a fixed cash amount and a long-term, conditional contract (the CVR).
• Leadership: The previous board of directors has stepped down, and Gilead now manages the company’s strategic direction.
• Patients: Development of anito-cel continues, now supported by Gilead’s global resources and infrastructure.

5. What should you do now?

• Verify your account: Confirm that your brokerage account shows the $115.00 cash credit.
• Track your CVR: Since the CVR is non-tradable, there is no active management required on your part. Simply keep a record of your CVR holdings and wait for updates regarding the sales performance of anito-cel as we approach 2030.
• Consult your tax professional: Because this acquisition involves a cash payout and a potential future payment, you may want to speak with a tax advisor to understand how this event impacts your specific tax situation for the 2026 tax year.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and does not constitute financial or tax advice. Always consult with a qualified professional regarding your specific investment portfolio and tax obligations.